TransMedics Group (NASDAQ:TMDX) reached a pivotal regulatory milestone Monday, receiving full and unconditional approval from the FDA to launch its next-generation OCS ENHANCE Heart trial.
Indianapolis-based Eli Lilly and Company (NYSE:LLY) announced on February 9, 2026, that it has agreed to acquire Orna Therapeutics, a biotechnology company pioneering circular RNA and novel lipid nanoparticle (LNP) delivery technologies for in vivo cell therapies.
Anavex Life Sciences (NASDAQ:AVXL) reported a narrowed net loss and a robust cash position for its fiscal first quarter, providing the clinical-stage biotech with a three-year financial cushion as it contests a regulatory setback in Europe and prepares for pivotal U.S. filings.
Edgewell Personal Care (NYSE:EPC) today reported first-quarter results that modestly exceeded internal expectations, as the company finalized a major strategic pivot by divesting its Feminine Care business to Essity for $340 million.
Novo Nordisk (NYSE:NVO) shares rebounded in Frankfurt on Monday after telehealth provider Hims & Hers Health (NYSE:HIMS) abruptly scrapped the launch of a low-cost, compounded weight-loss pill following an aggressive regulatory warning from the U.S. Food and Drug Administration.
Philip Morris International (NYSE:PM) reported fourth-quarter earnings that beat Wall Street expectations, driven by double-digit growth in its smoke-free portfolio and the continued dominance of ZYN nicotine pouches in the U.S. market.
Pfizer (NYSE:PFE) officially debuted its discount program on the TrumpRx platform Thursday, offering more than 30 branded medicines at steep price cuts as part of its "Most Favored Nation" (MFN) pact with the White House.
BioArctic (NASDAQ:B) reported a sharp rise in royalty income for the final quarter of 2025, as the global rollout of its Alzheimer’s treatment Leqembi continues to gain traction across major markets.
Telehealth leader Hims & Hers Health (NYSE:HIMS) sent shockwaves through the pharmaceutical sector on Thursday, announcing the launch of a compounded oral semaglutide pill priced significantly lower than Novo Nordisk’s brand-name Wegovy.
Bristol Myers Squibb (NYSE:BMY) shares gained 4% on Thursday after the pharmaceutical giant reported fourth-quarter results that surpassed expectations, signaling that its "Growth Portfolio" is successfully absorbing the impact of patent expirations on legacy blockbusters.
Omnicell (NASDAQ:OMCL) reported a record top-line performance for the full year 2025 on Thursday, though shares faced pressure as fourth-quarter earnings fell short of Wall Street's expectations due to higher-than-anticipated operating costs.
Cardinal Health (NYSE:CAH) delivered a blowout second quarter on Thursday, significantly raising its full-year outlook as the drug wholesaler cashes in on robust demand for specialty therapeutics and high-margin GLP-1 medications.
